Efficacy and Safety of Alteplase Combined with Urinarykallid for Intravenous Thrombolysis on Acute Cerebral Infarction

被引：2

作者：

Shao, Jiahui ^{[1
]}

Bao, Linyi ^{[1
]}

Jin, Xinchun ^{[1
]}

Jin, Haimiao ^{[1
]}

Chen, Yun ^{[2
]}

机构：

[1] First Peoples Hosp Wenling, Dept Neurol, Wenling 317500, Zhejiang, Peoples R China

[2] Taizhou Cent Hosp, Dept Neurol, Taizhou 318000, Zhejiang, Peoples R China

来源：

NEUROCHEMICAL JOURNAL | 2024年 / 18卷 / 01期

关键词：

alteplase; urinarykallid; acute cerebral infarction; efficacy; safety analysis; ISCHEMIC-STROKE; INFLAMMATION; TRIAL;

D O I：

10.1134/S1819712424010203

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

This study aimed to explore the efficacy and safety of alteplase combined with urinarykallid for the intravenous thrombolysis of patients with acute cerebral infarction. Patients (n = 125) who were admitted to our hospital were included and divided into Group A (n = 60) and Group B (n = 65). Patients in Group A were treated with alteplase for intravenous thrombolysis, based on which urinarykallid was administered to patients in Group B as a combination treatment. Compared to Group A, Group B was significantly lower in hs-CRP and TNF-alpha levels (p < 0.001), total incidence of adverse reactions (p < 0.05), and NIHSS score (p < 0.001) and higher in IL-10 level (p < 0.001), total effective rate (markedly effective + effective/total cases x 100%. Compared to the single administration of alteplase, the combination of alteplase and urinarykallid for the intravenous thrombolysis of patients with acute cerebral infarction can achieve better efficacy at a lower incidence of adverse reactions and play a more significant role in clinical treatment.

引用

页码：226 / 232

页数：7

共 26 条

[1] A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke [J].

Berkhemer, O. A. ;

Fransen, P. S. S. ;

Beumer, D. ;

van den Berg, L. A. ;

Lingsma, H. F. ;

Yoo, A. J. ;

Schonewille, W. J. ;

Vos, J. A. ;

Nederkoorn, P. J. ;

Wermer, M. J. H. ;

van Walderveen, M. A. A. ;

Staals, J. ;

Hofmeijer, J. ;

van Oostayen, J. A. ;

Nijeholt, G. J. Lycklama A. ;

Boiten, J. ;

Brouwer, P. A. ;

Emmer, B. J. ;

de Bruijn, S. F. ;

van Dijk, L. C. ;

Kappelle, L. J. ;

Lo, R. H. ;

Van Dijk, E. J. ;

de Vries, J. ;

de Kort, P. L. M. ;

van Rooij, W. J. J. ;

van den Berg, J. S. P. ;

van Hasselt, B. A. A. M. ;

Aerden, L. A. M. ;

Dallinga, R. J. ;

Visser, M. C. ;

Bot, J. C. J. ;

Vroomen, P. C. ;

Eshghi, O. ;

Schreuder, T. H. C. M. L. ;

Heijboer, R. J. J. ;

Keizer, K. ;

Tielbeek, A. V. ;

den Hertog, H. M. ;

Gerrits, D. G. ;

van den Berg-Vos, R. M. ;

Karas, G. B. ;

Steyerberg, E. W. ;

Flach, H. Z. ;

Marquering, H. A. ;

Sprengers, M. E. S. ;

Jenniskens, S. F. M. ;

Beenen, L. F. M. ;

van den Berg, R. ;

Koudstaal, P. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (01) :11-20

[2] Kallikrein-kinin in stroke, cardiovascular and renal disease [J].

Chao, J ;

Chao, L .

EXPERIMENTAL PHYSIOLOGY, 2005, 90 (03) :291-298

[3] The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015 [J].

Chen, Xiaoling ;

Wang, Kewei .

ACTA PHARMACEUTICA SINICA B, 2016, 6 (06) :522-530

[4] Human urinary kallidinogenase suppresses cerebral inflammation in experimental stroke and downregulates nuclear factor-κB [J].

Chen, Zhi-bin ;

Huang, Dan-qing ;

Niu, Feng-nan ;

Zhang, Xin ;

Li, Er-guang ;

Xu, Yun .

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2010, 30 (07) :1356-1365

[5]

Collaborative E.S.C.H.D., 1998, Lancet, V352, P1801, DOI [10.1016/S0140-6736(98)03454-0, DOI 10.1016/S0140-6736(98)03454-0]

[6] ALTEPLASE - A REAPPRAISAL OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN ACUTE MYOCARDIAL-INFARCTION [J].

GILLIS, JC ;

WAGSTAFF, AJ ;

GOA, KL .

DRUGS, 1995, 50 (01) :102-136

[7] Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke [J].

Goyal, M. ;

Demchuk, A. M. ;

Menon, B. K. ;

Eesa, M. ;

Rempel, J. L. ;

Thornton, J. ;

Roy, D. ;

Jovin, T. G. ;

Willinsky, R. A. ;

Sapkota, B. L. ;

Dowlatshahi, D. ;

Frei, D. F. ;

Kamal, N. R. ;

Montanera, W. J. ;

Poppe, A. Y. ;

Ryckborst, K. J. ;

Silver, F. L. ;

Shuaib, A. ;

Tampieri, D. ;

Williams, D. ;

Bang, O. Y. ;

Baxter, B. W. ;

Burns, P. A. ;

Choe, H. ;

Heo, J. -H. ;

Holmstedt, C. A. ;

Jankowitz, B. ;

Kelly, M. ;

Linares, G. ;

Mandzia, J. L. ;

Shankar, J. ;

Sohn, S. -I. ;

Swartz, R. H. ;

Barber, P. A. ;

Coutts, S. B. ;

Smith, E. E. ;

Morrish, W. F. ;

Weill, A. ;

Subramaniam, S. ;

Mitha, A. P. ;

Wong, J. H. ;

Lowerison, M. W. ;

Sajobi, T. T. ;

Hill, M. D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (11) :1019-1030

[8] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].

Hacke, W ;

Kaste, M ;

Fieschi, C ;

von Kummer, R ;

Davalos, A ;

Meier, D ;

Larrue, V ;

Bluhmki, E ;

Davis, S ;

Donnan, G ;

Schneider, D ;

Diez-Tejedor, E ;

Trouillas, P .

LANCET, 1998, 352 (9136) :1245-1251

[9]

Hacke W, 2004, LANCET, V363, P768

[10] Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke [J].

Hacke, Werner ;

Kaste, Markku ;

Bluhmki, Erich ;

Brozman, Miroslav ;

Davalos, Antoni ;

Guidetti, Donata ;

Larrue, Vincent ;

Lees, Kennedy R. ;

Medeghri, Zakaria ;

Machnig, Thomas ;

Schneider, Dietmar ;

von Kummer, Ruediger ;

Wahlgren, Nils ;

Toni, Danilo .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1317-1329

← 1 2 3 →